Front-line treatment of mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q42629494

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Front-line treatment of mantle cell lymphoma.

@en

Front-line treatment of mantle cell lymphoma.

@nl

type

Item

label

Front-line treatment of mantle cell lymphoma.

@en

Front-line treatment of mantle cell lymphoma.

@nl

prefLabel

Front-line treatment of mantle cell lymphoma.

@en

Front-line treatment of mantle cell lymphoma.

@nl

P1476

Front-line treatment of mantle cell lymphoma.

@en

P2093

Christian H Geisler

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

P304

1241-1243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2010.025627

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45440612

http://www.w3.org/2001/XMLSchema#string

P698

20675744

http://www.w3.org/2001/XMLSchema#string

P932

2913070

http://www.w3.org/2001/XMLSchema#string